Journals / The Journal of Breast Health / 2017 / Cilt: 13 - Sayı: 1

Background Parenchymal Enhancement and Fibroglandular Tissue Proportion on Breast MRI: Correlation with Hormone Receptor Expression and Molecular Subtypes of Breast Cancer

Pages
27–33
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

FGT proportion was also associated with BPE (p<0.001).Conclusion: In women with invasive breast cancer, both high FGT containing breasts and high BPE breasts tended to have ER positive tumors.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To assess the relationship between background parenchymal enhancement (BPE) and fibroglandular tissue (FGT) proportion on breast magnetic resonance imaging (MRI) and hormone receptor expression and molecular subtypes in invasive breast cancer.Materials and Methods: ftis retrospective study enrolled 75 breast cancer patients who underwent breast MRI before treatment.
📊
Key Findings & Data:T1-weighted images were reviewed to determine the FGT proportion, and contrast-enhanced fat-suppressed T1-weighted images were reviewed to determine BPE.
💡
Conclusion & Impact:FGT proportion was also associated with BPE (p<0.001).Conclusion: In women with invasive breast cancer, both high FGT containing breasts and high BPE breasts tended to have ER positive tumors.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: To assess the relationship between background parenchymal enhancement (BPE) and fibroglandular tissue (FGT) proportion on breast magnetic resonance imaging (MRI) and hormone receptor expression and molecular subtypes in invasive breast cancer.Materials and Methods: ftis retrospective study enrolled 75 breast cancer patients who underwent breast MRI before treatment. T1-weighted images were reviewed to determine the FGT proportion, and contrast-enhanced fat-suppressed T1-weighted images were reviewed to determine BPE. Estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2-neu (HER2) status, and molecular subtypes of the tumors were compared with the BPE and FGT proportions.Results: Women with high BPE tended to have increased rate of ER and PR positive tumors (p=0.018 and p=0.013). FGT proportion was associated with ER positivity (p=0.009), but no significant differences between FGT proportion and PR positivity were found (p=0.256). ftere was no significant difference between HER2 status and any of the imaging features (p=0.453 and p=0.922). For premenopausal women, both FGT proportion and BPE were associated with molecular subtypes (p=0.025 and p=0.042). FGT proportion was also associated with BPE (p<0.001).Conclusion: In women with invasive breast cancer, both high FGT containing breasts and high BPE breasts tended to have ER positive tumors.

🔖

Cite This Article

ÖZTÜRK, M., POLAT, A. V., SÜLLÜ, Y., TOMAK, L., POLAT, A. K. (2017). Background Parenchymal Enhancement and Fibroglandular Tissue Proportion on Breast MRI: Correlation with Hormone Receptor Expression and Molecular Subtypes of Breast Cancer. The Journal of Breast Health, Cilt: 13 - Sayı: 1, 27–33. https://ajindex.com/articles/362642

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program, http://seer.cancer.gov/statfacts/html/breast.html, 2013 [accessed 11.07.16]. Trop I, LeBlanc SM, David J, Lalonde L, Tran-Thanh D, Labelle M, El Khoury MM. Molecular classification of infiltrating breast cancer: to- ward personalized therapy. Radiographics 2014
  2. (PMID: 25208275) [CrossRef] Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, and panel members. Strategies for subtypes-dealing with the diver- sity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011
  3. (PMID: 21709140) [CrossRef] Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM. Epidemiology of basal-like breast cancer. Breast Cancer Res Tr 2008
  4. (PMID: 17578664) [CrossRef] Phipps AI, Buist DS, Malone KE, Barlow WE, Porter PL, Kerlikowske K, Li CI. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. Cancer Cause Control 2011
  5. (PMID: 21184265) [CrossRef] Aebi S, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Rabaglio M, Gelber RD, Crivellari D, Lindtner J, Snyder R, Karlsson P, Simon- cini E, Gusterson BA, Viale G, Regan MM, Coates AS, Goldhirsch A. Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX. Ann Oncol 2011
  6. (PMID: 21282282) [CrossRef] Nguyen PL, Taghian AG, Katz MS, Niemierko A, Raad RFA, Boon WL, 32 Bellon JR, Wong JS, Smith BL, Harris JR. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associ- ated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008
  7. (PMID: 18413639) [CrossRef] Wo JY, Taghian AG, Nguyen PL, Raad RA, Sreedhara M, Bellon JR, Wong JS, Gadd MA, Smith BL, Harris JR. The association between bio- logical subtype and isolated regional nodal failure after breast-conserv- ing therapy. Int J Radiat Oncol 2010
  8. (PMID: 20171798) [CrossRef] Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008
  9. (PMID: 18451135) [CrossRef] Saftlas AF, Hoover RN, Brinton LA, Szklo